Trial Profile
Risk stratified randomized controlled trial in paediatric Crohn's Disease: Methotrexate versus azathioprine or adalimumab for maintaining remission in patients at low or at high risk for aggressive disease course, respectively a treatment strategy
Status:
Recruiting
Phase of Trial:
Phase IV
Latest Information Update: 07 Jul 2022
Price :
$35
*
At a glance
- Drugs Adalimumab (Primary) ; Azathioprine (Primary) ; Mercaptopurine (Primary) ; Methotrexate (Primary)
- Indications Crohn's disease
- Focus Therapeutic Use
- Acronyms PIBDNet; RCT; REDUCE-RISK in CD-PIBD-TRIAL
- 03 Nov 2021 This trial has been completed in Netherlands.
- 16 May 2017 New trial record